A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
NCT02223598
Terminated
The purpose of this study is to determine the safety, tolerability, dose limiting toxicities, and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2018
Locations: City of Hope National Medical Center, Duarte, California +7 locations
Conditions: Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma
Register for Updates
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
NCT01002248
Terminated
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2018
Locations: Not set, La Verne, California +87 locations
Conditions: Multiple Myeloma
Register for Updates
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
NCT01270932
Completed
Primary: • To validate the initial dosing recommendations for newly diagnosed MM (Mutiple Myeloma) patients with various degrees of renal failure using pharmacokinetic studies Secondary: * To evaluate the safety of lenalidomide and dexamethasone as induction therapy in newly-diagnosed MM (Multiple Myeloma) patients with renal dysfunction using modified dosing guidelines * To evaluate clinical response of lenalidomide and dexamethasone after 4 cycles using the modified dosing guidelines * To e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2017
Locations: University Health Network- Princess Margaret Hosptial, Toronto, Ontario
Conditions: Renal Failure, Multiple Myeloma
Register for Updates
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
NCT00601172
Completed
This a Phase III trial designed to determine if IV casopitant plus dexamethasone and ondansetron is more effective in the prevention of vomiting and nausea then dexamethasone and ondansetrone alone following the administration of moderately emetogenic oxaliplatin-based chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2017
Locations: GSK Investigational Site, Hot Springs, Arkansas +95 locations
Conditions: Nausea and Vomiting, Chemotherapy-Induced
Register for Updates
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
NCT00562965
Terminated
This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin given with rituximab compared to a defined investigator's choice therapy. Subjects will be randomized to one of these two arms of the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/08/2017
Locations: Facey Medical Group, Mission Hills, California +38 locations
Conditions: Lymphoma, Follicular
Register for Updates
Dexamethasone in Total Knee and Total Hip Arthroplasty
NCT02760043
Unknown
This study will evaluate if the addition of dexamethasone to a local infiltration analgesia mixture will improve functional outcomes following total hip and knee arthroplasty.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/21/2017
Locations: Toronto Western Hopspital, Toronto, Ontario
Conditions: Total Knee Arthroplasty, Total Hip Arthroplasty, Osteoarthritis
Register for Updates
Evaluating Pain Outcomes of Caudal vs Ilioinguinal Nerve Block in Children Undergoing Hernia Repair
NCT03041948
Unknown
Surgical intervention to treat a inguinal hernia is a very common pediatric surgical procedure, often performed using an inguinal incision. Children who undergo hernia repair can suffer from a significant degree of discomfort postoperatively. The investigators are evaluating the effectiveness of an ultrasound guided caudal-epidural (CE) block to an US guided ilioinguinal/iliohypogastric (IIG/IHG) nerve block in achieving post operative analgesia following a hernia repair. It is hypothesized that... Read More
Gender:
ALL
Ages:
Between 6 months and 4 years
Trial Updated:
11/09/2017
Locations: Alberta Children's Hospital, Calgary, Alberta +1 locations
Conditions: Hernia, Inguinal, Pain, Postoperative
Register for Updates
Impact of Dexamethasone on the Duration of Sensory and Motor Block Following Spinal Anesthesia
NCT03078062
Completed
The purpose of this study is to assess the effect of a single-dose of intravenous dexamethasone 8 mg on the duration of sensory and motor blockade following spinal anesthesia with isobaric bupivacaine. The hypothesis of the study is that intravenous dexamethasone will significantly prolong (by more than 20 minutes) the duration of spinal anesthesia.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
10/26/2017
Locations: Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec
Conditions: Spinal Anesthesia, Prolonged Sensory Block, Prolonged Motor Block
Register for Updates
Effect of Dexamethasone Dose and Route on Duration of Interscalene Block After Outpatient Shoulder Surgery
NCT02426736
Completed
In this factorial design study, 280 participants having outpatient, arthroscopic shoulder surgery will be randomized into 4 equal sized groups. All participants will receive a standardized interscalene brachial plexus block and 4mg or 8mg of dexamethasone given by the intravenous or perineural (by the nerve with the nerve block) route just prior to their surgery. The purpose of this study is to determine which dose and route of dexamethasone provides the longest duration of pain control and the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2017
Locations: Pan Am Surgical Centre, Winnipeg, Manitoba
Conditions: Pain, Postoperative, Disorder of Shoulder
Register for Updates
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
NCT00056160
Completed
Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2017
Locations: Clinical Research Consultants, Inc., Hoover, Alabama +48 locations
Conditions: Multiple Myeloma
Register for Updates
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
NCT00724568
Completed
This research study is evaluating an investigational combination of four drugs called Revlimid® (lenalidomide), Velcade® (bortezomib), Dexamethasone and Doxil® (RVDD) as a possible treatment for newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2017
Locations: Emory University Hospital, Atlanta, Georgia +5 locations
Conditions: Multiple Myeloma
Register for Updates
Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia
NCT01133743
Completed
This is a phase II, non-randomized, single institution study in symptomatic, previously untreated CLL patients. All patients will receive the study drug, lenalidomide, given PO daily continuously on a 28 day cycle at the starting dose level of either 2.5 mgs or 5 mgs with dose escalations to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle. Patients will be treated with lenalidomide and dexamethasone to 2 cycles past CR o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2017
Locations: University Health Network - Princess Margaret Hospital, Toronto, Ontario
Conditions: Chronic Lymphocytic Leukemia
Register for Updates